Published in Hepatology on October 01, 1999
Mechanisms of hepatic fibrogenesis. Gastroenterology (2008) 11.98
Peginterferon Alfa-2a plus ribavirin versus interferon alfa-2a plus ribavirin for chronic hepatitis C in HIV-coinfected persons. N Engl J Med (2004) 7.67
The natural history of hepatitis C virus (HCV) infection. Int J Med Sci (2006) 3.13
Increasing prevalence of HCC and cirrhosis in patients with chronic hepatitis C virus infection. Gastroenterology (2010) 2.64
Co-infection with HIV and hepatitis C virus in former plasma/blood donors: challenge for patient care in rural China. AIDS (2006) 2.36
HIV monoinfection is associated with increased aspartate aminotransferase-to-platelet ratio index, a surrogate marker for hepatic fibrosis. J Infect Dis (2012) 2.30
Meta-analysis: increased mortality associated with hepatitis C in HIV-infected persons is unrelated to HIV disease progression. Clin Infect Dis (2009) 2.01
Using cohort studies to estimate mortality among injecting drug users that is not attributable to AIDS. Sex Transm Infect (2006) 1.92
Human immunodeficiency virus and hepatitis C infections induce distinct immunologic imprints in peripheral mononuclear cells. Hepatology (2009) 1.92
Assessment of liver fibrosis by transient elastography in persons with hepatitis C virus infection or HIV-hepatitis C virus coinfection. Clin Infect Dis (2009) 1.80
Liver fibrosis during an outbreak of acute hepatitis C virus infection in HIV-infected men: a prospective cohort study. J Infect Dis (2008) 1.78
Coinfection with HIV-1 and HCV--a one-two punch. Gastroenterology (2009) 1.78
Validity of diagnostic codes and liver-related laboratory abnormalities to identify hepatic decompensation events in the Veterans Aging Cohort Study. Pharmacoepidemiol Drug Saf (2011) 1.76
Advancing donor liver age and rapid fibrosis progression following transplantation for hepatitis C. Gut (2002) 1.65
Hepatic decompensation in antiretroviral-treated patients co-infected with HIV and hepatitis C virus compared with hepatitis C virus-monoinfected patients: a cohort study. Ann Intern Med (2014) 1.64
Impact of human immunodeficiency virus (HIV) infection on the progression of liver fibrosis in hepatitis C virus infected patients. Gut (2003) 1.48
The burden of hepatitis C virus infection is growing: a Canadian population-based study of hospitalizations from 1994 to 2004. Can J Gastroenterol (2008) 1.46
Coinfection with hepatitis C virus and human immunodeficiency virus: virological, immunological, and clinical outcomes. J Virol (2009) 1.41
Modulation of HCV replication after combination antiretroviral therapy in HCV/HIV co-infected patients. Sci Transl Med (2014) 1.39
Liver disease in the HIV-infected individual. Clin Gastroenterol Hepatol (2010) 1.33
The changing burden of hepatitis C virus infection in the United States: model-based predictions. Ann Intern Med (2014) 1.33
Clinical presentation and course of acute hepatitis C infection in HIV-infected patients. J Acquir Immune Defic Syndr (2006) 1.32
Hepatitis C virus genotype 3a infection and hepatocellular carcinoma: Pakistan experience. World J Gastroenterol (2009) 1.31
Comparison of hepatitis C viral loads in patients with or without human immunodeficiency virus. Clin Diagn Lab Immunol (2001) 1.24
Management of hepatitis C virus infection in HIV/HCV co-infected patients: clinical review. World J Gastroenterol (2009) 1.22
Assessing mortality in women with hepatitis C virus and HIV using indirect markers of fibrosis. AIDS (2012) 1.21
Therapeutic issues in HIV/HCV-coinfected patients. J Viral Hepat (2007) 1.20
Fibrosis progression in African Americans and Caucasian Americans with chronic hepatitis C. Clin Gastroenterol Hepatol (2008) 1.19
Reversal, maintenance or progression: what happens to the liver after a virologic cure of hepatitis C? Antiviral Res (2014) 1.17
HCV and HIV co-infection: mechanisms and management. Nat Rev Gastroenterol Hepatol (2014) 1.16
Pathogenesis of accelerated fibrosis in HIV/HCV co-infection. J Infect Dis (2013) 1.14
Managing occupational risks for hepatitis C transmission in the health care setting. Clin Microbiol Rev (2003) 1.13
Hepatitis C infection in HIV-1 natural viral suppressors. AIDS (2010) 1.13
Hepatitis C and HIV co-infection: a review. World J Gastroenterol (2002) 1.12
Hepatitis C and HIV-1 coinfection. Gut (2002) 1.12
Hepatitis C virus is infrequently evaluated and treated in an urban HIV clinic population. AIDS Patient Care STDS (2009) 1.10
HIV care providers' implementation of routine alcohol reduction support for their patients. AIDS Patient Care STDS (2009) 1.09
Host-specific response to HCV infection in the chimeric SCID-beige/Alb-uPA mouse model: role of the innate antiviral immune response. PLoS Pathog (2006) 1.09
Human immunodeficiency virus seroconversion and evolution of the hepatitis C virus quasispecies. J Virol (2001) 1.08
Influence of cannabis use on severity of hepatitis C disease. Clin Gastroenterol Hepatol (2008) 1.08
Fibrosis progression in human immunodeficiency virus/hepatitis C virus coinfected adults: prospective analysis of 435 liver biopsy pairs. Hepatology (2014) 1.08
Neuropsychological aspects of coinfection with HIV and hepatitis C virus. Clin Infect Dis (2005) 1.07
Interleukin-27, an anti-HIV-1 cytokine, inhibits replication of hepatitis C virus. J Interferon Cytokine Res (2010) 1.07
Screening for hepatitis C among HIV positive patients at Mulago hospital in Uganda. Afr Health Sci (2009) 1.04
Efficacy and safety of telaprevir in patients with genotype 1 hepatitis C infection. Therap Adv Gastroenterol (2012) 1.03
Management of chronic hepatitis C. Postgrad Med J (2005) 1.03
Indian National Association for Study of the Liver (INASL) Guidance for Antiviral Therapy Against HCV Infection: Update 2016. J Clin Exp Hepatol (2016) 1.02
Molecular mechanisms of liver fibrosis in HIV/HCV coinfection. Int J Mol Sci (2014) 1.01
Proteome-wide anti-hepatitis C virus (HCV) and anti-HIV antibody profiling for predicting and monitoring the response to HCV therapy in HIV-coinfected patients. J Infect Dis (2010) 1.01
Clinical spectrum and histopathologic features of chronic hepatitis C infection in children. J Pediatr (2007) 1.01
Profibrogenic chemokines and viral evolution predict rapid progression of hepatitis C to cirrhosis. Proc Natl Acad Sci U S A (2012) 1.01
Kupffer cells are depleted with HIV immunodeficiency and partially recovered with antiretroviral immune reconstitution. AIDS (2009) 1.00
Treatment outcomes of treatment-naïve Hepatitis C patients co-infected with HIV: a systematic review and meta-analysis of observational cohorts. PLoS One (2013) 0.99
Infectious disease comorbidities adversely affecting substance users with HIV: hepatitis C and tuberculosis. J Acquir Immune Defic Syndr (2010) 0.98
Social determinants of health associated with hepatitis C co-infection among people living with HIV: results from the Positive Spaces, Healthy Places study. Open Med (2011) 0.98
Sustained long-term antiviral maintenance therapy in HCV/HIV-coinfected patients (SLAM-C). J Acquir Immune Defic Syndr (2010) 0.97
Epidemiology of hepatitis C virus infection & liver disease among injection drug users (IDUs) in Chennai, India. Indian J Med Res (2010) 0.96
HCV co-infection in HIV positive population in British Columbia, Canada. BMC Public Health (2010) 0.95
Role of GB virus C in modulating HIV disease. Expert Rev Anti Infect Ther (2012) 0.95
HIV infection increases HCV-induced hepatocyte apoptosis. J Hepatol (2010) 0.95
Hepatitis C viral kinetics during treatment with peg IFN-alpha-2b in HIV/HCV coinfected patients as a function of baseline CD4+ T-cell counts. J Acquir Immune Defic Syndr (2009) 0.94
Impact of human immunodeficiency virus infection on the course of hepatitis C virus infection: a meta-analysis. World J Gastroenterol (2009) 0.94
Hepatitis C and HIV co-infection: new drugs in practice and in the pipeline. Curr HIV/AIDS Rep (2012) 0.94
Biomarkers of inflammation and coagulation are associated with mortality and hepatitis flares in persons coinfected with HIV and hepatitis viruses. J Infect Dis (2013) 0.93
HIV and liver disease forum: conference proceedings. Hepatology (2007) 0.93
Barriers to hepatitis C virus treatment in a Canadian HIV-hepatitis C virus coinfection tertiary care clinic. Can J Gastroenterol (2008) 0.93
Steatohepatitis: Risk factors and impact on disease severity in human immunodeficiency virus/hepatitis C virus coinfection. Hepatology (2008) 0.92
Interleukin-6 is associated with noninvasive markers of liver fibrosis in HIV-infected patients with alcohol problems. AIDS Res Hum Retroviruses (2013) 0.92
Predicting the probable outcome of treatment in HCV patients. Therap Adv Gastroenterol (2009) 0.92
HCV-HIV coinfection: simple messages from a complex disease. PLoS Med (2007) 0.91
Opioids and HIV/HCV infection. J Neuroimmune Pharmacol (2011) 0.91
Association of HIV infection, hepatitis C virus infection, and metabolic factors with liver stiffness measured by transient elastography. J Infect Dis (2013) 0.90
Hepatitis C treatment experiences and decision making among patients living with HIV infection. J Assoc Nurses AIDS Care (2009) 0.90
Similar progression of fibrosis between HIV/HCV-infected and HCV-infected patients: Analysis of paired liver biopsy samples. Clin Gastroenterol Hepatol (2010) 0.90
The role of co-infections in mother-to-child transmission of HIV. Curr HIV Res (2013) 0.90
Impact of Cryoglobulinemic Syndrome on the Outcome of Chronic Hepatitis C Virus Infection: A 15-Year Prospective Study. Medicine (Baltimore) (2013) 0.90
Antigen-specific immune responses and liver histology in HIV and hepatitis C coinfection. AIDS (2005) 0.89
Clinical Monitoring of Chronic Hepatitis C Based on its Natural History and Therapy. N Am J Med Sci (Boston) (2014) 0.88
Therapeutic challenges in hepatitis C-infected injection drug using patients. Harm Reduct J (2006) 0.88
Unhealthy alcohol use, HIV infection and risk of liver fibrosis in drug users with hepatitis C. PLoS One (2012) 0.88
Association of interleukin-15-induced peripheral immune activation with hepatic stellate cell activation in persons coinfected with hepatitis C virus and HIV. J Infect Dis (2009) 0.88
The Tat protein of human immunodeficiency virus-1 enhances hepatitis C virus replication through interferon gamma-inducible protein-10. BMC Immunol (2012) 0.88
Rapid progression to decompensated cirrhosis, liver transplant, and death in HIV-infected men after primary hepatitis C virus infection. Clin Infect Dis (2012) 0.88
Natural history of hepatitis C infection: a concise review. Yale J Biol Med (2001) 0.87
Clinical features and outcome of spontaneous bacterial peritonitis in HIV-infected cirrhotic patients: a case-control study. Eur J Clin Microbiol Infect Dis (2006) 0.87
Clinical Liver Disease Progression Among Hepatitis C-Infected Drug Users With CD4 Cell Count Less Than 200 Cells/mm(3) Is More Pronounced Among Women Than Men. Open Forum Infect Dis (2015) 0.87
Hepatocellular carcinoma prevalence and mortality in a male state prison population. Public Health Rep (2009) 0.87
The expression of HIV-1 Vpu in monocytes causes increased secretion of TGF-β that activates profibrogenic genes in hepatic stellate cells. PLoS One (2014) 0.87
The pharmacologic management of insomnia in patients with HIV. J Clin Sleep Med (2009) 0.87
The impact of human T-cell lymphotropic virus I infection on clinical and immunologic outcomes in patients coinfected with HIV and hepatitis C virus. J Acquir Immune Defic Syndr (2011) 0.86
Extended therapy with pegylated interferon and weight-based ribavirin for HCV-HIV coinfected patients. HIV Clin Trials (2012) 0.86
Meningococcemia in a patient coinfected with hepatitis C virus and HIV. Emerg Infect Dis (2001) 0.86
Silibinin inhibits HIV-1 infection by reducing cellular activation and proliferation. PLoS One (2012) 0.86
Recommendations for the Clinical Management of Hepatitis C in Iran: A Consensus-Based National Guideline. Hepat Mon (2016) 0.86
Engaging HIV-HCV co-infected patients in HCV treatment: the roles played by the prescribing physician and patients' beliefs (ANRS CO13 HEPAVIH cohort, France). BMC Health Serv Res (2012) 0.85
Reliability and predictive validity of a hepatitis-related symptom inventory in HIV-infected individuals referred for Hepatitis C treatment. AIDS Res Ther (2011) 0.85
Role of liver transplantation in human immunodeficiency virus positive patients. World J Gastroenterol (2015) 0.85
An algorithm for the grading of activity in chronic hepatitis C. The METAVIR Cooperative Study Group. Hepatology (1996) 12.47
Positive effects of combined antiretroviral therapy on CD4+ T cell homeostasis and function in advanced HIV disease. Science (1997) 10.35
Natural history of liver fibrosis progression in patients with chronic hepatitis C. The OBSVIRC, METAVIR, CLINIVIR, and DOSVIRC groups. Lancet (1997) 10.05
Isolation of a new human retrovirus from West African patients with AIDS. Science (1986) 7.97
Decline in the AIDS and death rates in the EuroSIDA study: an observational study. Lancet (2003) 7.94
The retrieval of randomized clinical trials in liver disease from the medical literature. A comparison of MEDLARS and manual methods. Control Clin Trials (1985) 6.22
Biochemical markers of liver fibrosis in patients with hepatitis C virus infection: a prospective study. Lancet (2001) 5.82
Quantitation of MYC gene expression in sporadic breast tumors with a real-time reverse transcription-PCR assay. Cancer Res (1999) 4.74
Estimating future hepatitis C morbidity, mortality, and costs in the United States. Am J Public Health (2000) 3.82
Rates and risk factors of liver fibrosis progression in patients with chronic hepatitis c. J Hepatol (2001) 3.64
Liver fibrosis in overweight patients. Gastroenterology (2000) 3.56
Long-lasting recovery in CD4 T-cell function and viral-load reduction after highly active antiretroviral therapy in advanced HIV-1 disease. Lancet (1998) 3.45
Propranolol for prevention of recurrent gastrointestinal bleeding in patients with cirrhosis: a controlled study. N Engl J Med (1981) 3.13
Mycobacterium simiae and Mycobacterium avium-M. intracellulare mixed infection in acquired immune deficiency syndrome. J Clin Microbiol (1987) 3.01
Perturbation of CD4+ and CD8+ T-cell repertoires during progression to AIDS and regulation of the CD4+ repertoire during antiviral therapy. Nat Med (1998) 2.99
Identification of CD8+CD25+Foxp3+ suppressive T cells in colorectal cancer tissue. Gut (2008) 2.97
Prenatal diagnosis of congenital toxoplasmosis with a polymerase-chain-reaction test on amniotic fluid. N Engl J Med (1994) 2.94
Peptic ulcer bleeding in patients with or without cirrhosis: different diseases but the same prognosis? Aliment Pharmacol Ther (2012) 2.68
Novel approach to quantitative polymerase chain reaction using real-time detection: application to the detection of gene amplification in breast cancer. Int J Cancer (1998) 2.52
Neurodegenerative diseases and oxidative stress. Biomed Pharmacother (2004) 2.44
High glucose and hyperinsulinemia stimulate connective tissue growth factor expression: a potential mechanism involved in progression to fibrosis in nonalcoholic steatohepatitis. Hepatology (2001) 2.41
Non-Hodgkin lymphoma in HIV-infected patients in the era of highly active antiretroviral therapy. Blood (2001) 2.37
Long-term incidence of hepatitis B virus resistance to lamivudine in human immunodeficiency virus-infected patients. Hepatology (1999) 2.36
Influence of delta infection on severity of hepatitis B. Lancet (1982) 2.31
Factors associated with a reduced CD4 lymphocyte count response to HAART despite full viral suppression in the EuroSIDA study. HIV Med (2003) 2.30
Factors affecting liver fibrosis in human immunodeficiency virus-and hepatitis C virus-coinfected patients: impact of protease inhibitor therapy. Hepatology (2001) 2.29
Detection of Aspergillus species DNA in bronchoalveolar lavage samples by competitive PCR. J Clin Microbiol (1995) 2.28
Meta-analysis of interferon randomized trials in the treatment of viral hepatitis C: effects of dose and duration. Hepatology (1996) 2.22
Antibiotic prophylaxis for the prevention of bacterial infections in cirrhotic patients with gastrointestinal bleeding: a meta-analysis. Hepatology (1999) 2.18
AIDS across Europe, 1994-98: the EuroSIDA study. Lancet (2000) 2.13
HIV-1 infection in an individual homozygous for CCR5 delta 32. Seroco Study Group. Lancet (1997) 2.11
Impact of hepatitis B and C virus on kidney transplantation outcome. Hepatology (1999) 2.11
Hepatitis C virus and essential mixed cryoglobulinaemia. Br J Rheumatol (1993) 2.08
Corticosteroids and peptic ulcer: meta-analysis of adverse events during steroid therapy. J Intern Med (1994) 2.05
Detection of Toxoplasma gondii by competitive DNA amplification of bronchoalveolar lavage samples. J Infect Dis (1993) 2.04
Changes in AIDS-related lymphoma since the era of highly active antiretroviral therapy. Blood (2001) 1.98
Survival of AIDS patients according to type of AIDS-defining event. The AIDS in Europe Study Group. Int J Epidemiol (1997) 1.97
Anti-RhoA and anti-RhoC siRNAs inhibit the proliferation and invasiveness of MDA-MB-231 breast cancer cells in vitro and in vivo. Mol Ther (2005) 1.95
Safety and efficacy of interferon-ribavirin combination therapy in HCV-HIV coinfected subjects: an early report. Gut (2000) 1.94
Expression of connective tissue growth factor in experimental rat and human liver fibrosis. Hepatology (1999) 1.94
High rate of virologic suppression with raltegravir plus etravirine and darunavir/ritonavir among treatment-experienced patients infected with multidrug-resistant HIV: results of the ANRS 139 TRIO trial. Clin Infect Dis (2009) 1.89
Estimating the future health burden of chronic hepatitis C and human immunodeficiency virus infections in the United States. J Viral Hepat (2007) 1.86
Nevirapine-containing antiretroviral therapy in HIV-1 infected patients results in an anti-atherogenic lipid profile. AIDS (2001) 1.81
Germ-line deletion involving the INK4 locus in familial proneness to melanoma and nervous system tumors. Cancer Res (1998) 1.80
Management of focal nodular hyperplasia and hepatocellular adenoma in young women: a series of 41 patients with clinical, radiological, and pathological correlations. Hepatology (1995) 1.78
Extrahepatic manifestations of chronic hepatitis C. MULTIVIRC Group. Multidepartment Virus C. Arthritis Rheum (1999) 1.77
HIV-1 rebound during interruption of highly active antiretroviral therapy has no deleterious effect on reinitiated treatment. Comet Study Group. AIDS (1999) 1.75
Real-time reverse transcription-PCR assay for future management of ERBB2-based clinical applications. Clin Chem (1999) 1.74
Remission from Kaposi's sarcoma on HAART is associated with suppression of HIV replication and is independent of protease inhibitor therapy. Br J Cancer (2006) 1.73
Evaluation of androgen, estrogen (ER alpha and ER beta), and progesterone receptor expression in human prostate cancer by real-time quantitative reverse transcription-polymerase chain reaction assays. Cancer Res (2001) 1.72
T cell receptor gamma/delta+ lymphocyte subsets during HIV infection. Clin Exp Immunol (1989) 1.72
A randomized trial of prednisolone in patients with severe alcoholic hepatitis. N Engl J Med (1992) 1.71
Resistance profile and cross-resistance of HIV-1 among patients failing a non-nucleoside reverse transcriptase inhibitor-containing regimen. J Med Virol (2001) 1.68
The level of human immunodeficiency virus (HIV) type 1 RNA in cerebrospinal fluid as a marker of HIV encephalitis. Clin Infect Dis (1998) 1.67
Changing of hepatitis C virus genotype patterns in France at the beginning of the third millenium: The GEMHEP GenoCII Study. J Viral Hepat (2005) 1.64
CD4+Ki67+ lymphocytes in HIV-infected patients are effector T cells accumulated in the G1 phase of the cell cycle. Eur J Immunol (2000) 1.62
Modeling the hepatitis C virus epidemic in France. Hepatology (1999) 1.61
Natural history of HCV infection. Baillieres Best Pract Res Clin Gastroenterol (2000) 1.61
Performance and limitations of steatosis biomarkers in patients with nonalcoholic fatty liver disease. Aliment Pharmacol Ther (2014) 1.60
Dermatoses associated with travel to tropical countries: a prospective study of the diagnosis and management of 269 patients presenting to a tropical disease unit. Clin Infect Dis (1995) 1.59
Multivariate analysis of prognostic factors in fulminant hepatitis B. Hepatology (1986) 1.59
Factor VIII gene inversions in severe hemophilia A: results of an international consortium study. Blood (1995) 1.59
Real-time PCR as a new tool for quantifying Leishmania infantum in liver in infected mice. Clin Diagn Lab Immunol (2001) 1.58
Cost-effectiveness of 24 or 48 weeks of interferon alpha-2b alone or with ribavirin as initial treatment of chronic hepatitis C. International Hepatitis Interventional Therapy Group. Am J Gastroenterol (2000) 1.57
HIV-1-associated cognitive/motor complex: absence of neuronal loss in the cerebral neocortex. Neurology (1993) 1.56
Trends in primary liver cancer. Lancet (1998) 1.56
Common bile duct stricture as a late complication of upper abdominal radiotherapy. J Hepatol (1994) 1.56
A two-centre, randomized, double-blind trial of ornithine oxoglutarate in 194 elderly, ambulatory, convalescent subjects. Age Ageing (1994) 1.56
Insulin resistance and geographical origin: major predictors of liver fibrosis and response to peginterferon and ribavirin in HCV-4. Gut (2009) 1.56
A randomized controlled study of propranolol for prevention of recurrent gastrointestinal bleeding in patients with cirrhosis: a final report. Hepatology (1984) 1.56
Quantitation of minimal residual disease in acute promyelocytic leukemia patients with t(15;17) translocation using real-time RT-PCR. Leukemia (2000) 1.55
European AIDS Clinical Society (EACS) guidelines on the prevention and management of metabolic diseases in HIV. HIV Med (2008) 1.54
Quantitation of hTERT gene expression in sporadic breast tumors with a real-time reverse transcription-polymerase chain reaction assay. Clin Cancer Res (2000) 1.53